Related Experiment Video
Updated: May 17, 2026
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Epigenetic profile in chronic lymphocytic leukemia using methylation-specific multiplex ligation-dependent probe
Ana M Cosialls1, Antonio F Santidrián, Llorenç Coll-Mulet
1Departament de Ciències Fisiològiques II, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)-Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Hypermethylation of tumor suppressor genes is common in chronic lymphocytic leukemia (CLL). Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) effectively detects these changes, aiding in risk stratification and treatment decisions for CLL patients.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Aberrant DNA methylation is implicated in cancer development.
- Chronic lymphocytic leukemia (CLL) pathogenesis involves epigenetic alterations.
- Understanding methylation patterns is crucial for CLL diagnosis and prognosis.
Purpose of the Study:
- To investigate the methylation status of 35 tumor suppressor genes in CLL.
- To evaluate the utility of methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) for detecting gene methylation in CLL.
- To identify frequently hypermethylated genes in CLL samples.
Main Methods:
- DNA from 37 CLL patients, 6 healthy donors, and cell lines was analyzed using MS-MLPA.
- Bisulfite sequencing was employed to confirm methylation status of novel targets.
- Analysis focused on 35 specific tumor suppressor genes.
Main Results:
- Hypermethylation is a frequent and non-random event in CLL.
- Genes like WT1, CDH13, IGSF4/TSLC1, GATA5, DAPK1, and RARB were hypermethylated in over 25% of samples.
- MS-MLPA identified previously unreported hypermethylated genes in CLL, validated by bisulfite sequencing.
Conclusions:
- MS-MLPA is a valuable tool for detecting DNA methylation in CLL.
- Developing CLL-specific MS-MLPA probe sets can improve its application in risk stratification.
- This technique can aid in guiding therapeutic decisions for CLL patients.
